Zacks Investment ResearchT3·17d ago
XRAY DENTSPLY SIRONA Inc.
XNAS
9.61
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
XRAY
$9.61
—
Key stats
$9.61
- 52-Week Range
- $8.32 – $14.76
- YTD
- -14.73%
- IV Rank (30D)
- 26.72
- Straddle Price
- $1.12
- P/C Vol Ratio
- 0.23
- Market Cap
- $1.9B
- Open
- $9.53
- Day Range
- $9.47 – $9.77
- Volume
- 3,552,032
- Prev Close
- $9.44
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.99% |
| Beta vs SPY | 0.93 |
| Cost of Equity (CAPM) | 9.62% (VRP-adj) |
| WACC | 7.34% |
| Volatility Risk Premium | +104.9pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -0.7% |
| DCF Horizon | 5 years explicit + fade |
| Free Cash Flow (TTM) | $0.1B |
| Return on Equity (TTM) | -40.4% |
| Book / Price | 70.4% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 49.5% |
| FCF Margin (TTM) | 3.9% |
| Debt / Equity | 1.48 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| Market-Implied Growth | +6.9% (reverse-DCF on current price) |
| SMA 50 | $9.72 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $8.88 |
| Bollinger Width / SMA20 | 199.9% (drives anchor stability) |
| Net Debt | $1.8B |
| Market Cap | $2B |
Peers used for multiples: ALGN, ELAN, MDT, TFX, ZBH
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
3%
20-Day Fair Value
≈ by Nov 30, 2026
$9.67
α +0.6%
rank 89%
conviction
41%
40-Day Fair Value
≈ by Dec 29, 2026
$9.80
α +1.9%
rank 89%
conviction
64%
60-Day Fair Value
≈ by Jan 27, 2027
$9.60
α -0.1%
rank 89%
conviction
3%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $4.34 | 29% | |
| DDM (Gordon) | $1.55 | 0% | |
| Peer P/E | n/a | 0% | median 23.2× · 3 peers |
| Peer EV/EBITDA | $29.61 | 9% | median 14.4× · 5 peers |
| Peer P/B | $13.72 | 11% | median 2.0× · 5 peers |
| Peer P/S | $48.13 | 11% | median 2.6× · 5 peers |
| Market Anchor (SMA50) | $9.72 | 40% | stability 69% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-30 · updated
Related
About
- Industry (SIC)
- DENTAL EQUIPMENT & SUPPLIES (3843) · industry map
- Exchange
- XNAS
- Market Cap
- $1.9B
- Employees
- 14,000
- List Date
- 1983-05-12
- CIK
- 0000818479
- Next Earnings
- 2026-11-05 (After-Close)
- EPS Forecast
- $0.31
- Headquarters
- Charlotte, NC
- Homepage
- https://www.dentsplysirona.com
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantology. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining po…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -0.48% | -6.10% | 12.66% | -2.47% | 5.39% | 10.65% | 3.27% |
| Feb | -1.58% | 1.94% | 1.57% | -5.82% | -14.47% | 20.23% | 0.31% |
| Mar | 6.87% | -9.46% | 5.14% | -0.24% | -6.57% | -18.94% | -3.87% |
| Apr | 6.42% | -18.80% | 7.21% | -6.95% | -5.12% | 0.77% | -2.75% |
| May | -1.60% | -0.23% | -14.79% | -7.19% | 14.72% | -11.35% | -3.41% |
| Jun | -6.09% | -8.48% | 6.27% | -11.16% | 1.66% | 5.89% | -1.99% |
| Jul | 3.14% | -0.11% | 4.85% | 10.19% | -13.48% | 21.16% | 4.29% |
| Aug | -7.51% | -8.92% | -10.35% | -5.39% | 0.00% | -20.95% | -8.85% |
| Sep | -5.50% | -11.87% | -8.86% | 8.24% | -8.11% | -17.66% | -7.29% |
| Oct | -3.15% | 5.62% | -9.98% | -11.29% | -2.63% | 9.95%* | -1.91% |
| Nov | -16.14% | -2.39% | 2.95% | -16.35% | -9.64% | -- | -8.31% |
| Dec | 15.48% | 1.27% | 9.34% | -4.24% | 2.24% | -- | 4.82% |
| Total | -12.96% | -46.21% | 1.39% | -43.63% | -33.35% | -11.55% | -24.39% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $8.88
SMA 50: $9.72
SMA 200: $11.34
Current: $9.61
EMA 12: $9.19
EMA 26: $9.25
MACD: -0.0519 | Signal: 0.1734
BEARISH
ADX (14): 27.49
TREND
+DI: 29.26
−DI: 18.17
Momentum Oscillators
RSI (14): 56.80
NEUTRAL
Stoch %K: 87.92
Stoch %D: 84.32
Williams %R: -11.03
Volume & Volatility
BB Upper: $9.67
BB Lower: $8.09
NEUTRAL
OBV: -71,574,036
Vol SMA 20: 4,521,537
Vol ROC: -31.47%
ATR: $0.34
True Range: $0.33
HV 20: 38.8%
HV 30: 39.2%
HV 60: 43.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-31T00:00:00 – 2026-10-29T00:00:00
AI Analysis
XRAY (Dentsply Sirona) - Comprehensive Stock Analysis
Executive Summary
Overall Assessment: BEARISH with Confidence Level: 6/10
Dentsply Sirona presents a conflicted technical and sentiment picture. While positive news sentiment surrounding dental market growth and company expansion initiatives is encouraging, the stock is trapped in a near-term bearish technical structure with significant momentum divergences. The company is trading near overbought conditions on a tactical basis, but with underlying weakness in trend structure and negative MACD signals that suggest momentum is fading despite the current price elevation.
Key Drivers:
- Positive: Expansion of U.S. distribution network, favorable dental market growth forecasts, Q2 earnings beat
- Primary Risks: Bearish MACD divergence, negative OBV, elevated IV pricing, deteriorating volume trends, margin pressure concerns
Investment Thesis: XRAY shows positive long-term sector tailwinds and company-specific execution (distribution expansion, market share gains in $14.42B implant market), but near-term technicals suggest profit-taking is likely before the next earnings catalyst on November 5, 2026. The overbought Bollinger Band position combined with bearish MACD and high put/call ratios indicates traders are hedging against pullback risk despite fundamentally constructive news flow.
Recent News Sentiment Impact: News sentiment is POSITIVE (5 of 6 recent headlines favorable), but critically, these positive announcements have NOT driven sustained price appreciation—price remains below the 50-day and 200-day moving averages, suggesting institutional investors are being selective or taking profits on news. The most recent headline (Midwest expansion on 2026-10-12) appears to coincide with current price levels but hasn't broken the stock above key resistance.
Technical Analysis
Trend Direction
| Timeframe | Direction | Assessment | |-----------|-----------|-----------| | Short-term (1-4 weeks) | BEARISH | Price at $9.43 sits between SMA20 ($8.79) and SMA50 ($9.87). The position just above the 20-day MA suggests fragile support; price is still -17.3% below the 200-day MA ($11.41). | | Medium-term (1-3 months) | BEARISH | SMA50 ($9.87) > Price ($9.43), confirming downtrend. The 50/200 MA bearish alignment (9.87 < 11.41) indicates sustained weakness. | | Long-term (3-12 months) | BEARISH | Price is 17.3% below the 200-day MA, suggesting a longer-term downtrend from peaks above $11.41. No evidence of recovery trend formation. |
Support/Resistance Levels
Critical Levels to Monitor:
| Level | Type | Implication | |-------|------|------------| | $8.79 | Dynamic Support (SMA20) | Immediate support; break below signals acceleration downward | | $8.17 | Support (Lower Bollinger Band) | Secondary support; represents extreme oversold if reached | | $9.18-$9.87 | Resistance Zone (EMA26, SMA50) | Strong resistance cluster; sustained break above needed for bullish reversal | | $11.41 | Major Resistance (SMA200) | Psychological and technical barrier; reclaiming this level would reverse medium/long-term outlook |
Momentum Signals
RSI (14): 53.98 — NEUTRAL
- RSI sits in the neutral zone (30-70), neither overbought nor oversold on an absolute basis
- However, RSI is notably declining while price holds near highs—classic bearish divergence signal
- Suggests momentum is weakening despite price stability; pullback likely when RSI breaks below 50
MACD: -0.22 / Signal: 0.18 / Histogram: -0.40 — BEARISH
- Critical bearish signal: MACD (-0.22) is below its signal line (0.18), indicating bearish crossover
- The negative histogram (-0.40) confirms momentum is shifting downward
- This divergence is particularly concerning because it's happening while the stock appears strong tactically—suggests the move higher lacks conviction
Stochastic Oscillators — EXTREME OVERBOUGHT
- Stochastic %K: 95.39 (extremely overbought, typically >80 is overbought territory)
- Stochastic %D: 85.79 (also extremely elevated)
- Williams %R: -9.76 (extremely overbought)
- Signal: These readings typically precede sharp reversals; the stock has extended beyond normal ranges
Bollinger Bands: OVERBOUGHT
- Upper Band: $9.42 (price at $9.43—literally touching the band)
- Price is touching/marginally above the upper band, indicating mean reversion risk
- Band width is 14.24%, suggesting moderate volatility but not extreme; room for compression
- Signal: Price is at the statistical extreme; pullback toward middle band ($8.79) is typical from this position
Volume Analysis
Volume Deterioration — Bearish Signal:
- Volume SMA 20: 4,920,692 (baseline average)
- Volume Rate of Change: -12.25% (negative, indicating declining participation)
- Interpretation: Current volume is running 12% below recent average, suggesting declining conviction in the current price level
On-Balance Volume (OBV): -80,939,613.16 — NEGATIVE
- Deeply negative OBV indicates cumulative selling pressure over recent trading
- OBV failing to confirm price strength is a classic bearish divergence
- Suggests institutional or informed investors are distributing shares on rallies
Institutional Activity Signal:
- Combination of -12.25% volume ROC and negative OBV strongly suggests institutional accumulation on previous weakness has reversed to distribution
- Volume should be expanding on price strength; the decline in volume + negative OBV indicates institutions are selling into strength
News & Sentiment Analysis
Recent Headlines Summary
| Date | Headline | Sentiment | Relevance | |------|----------|-----------|-----------| | 2026-10-12 | Midwest Distribution Expansion | POSITIVE | Recent; operational expansion (catalyst for Q4 growth) | | 2026-09-08 | Q2 Earnings Beat with Margin Pressure | NEUTRAL | Mixed: beat on earnings, but margin concerns flag profitability questions | | 2026-07-09 | Dental Implant Market $14.42B by 2034 | POSITIVE | TAM (Total Addressable Market) growth story | | 2026-07-03 | Dental Imaging Market $4.74B by 2031 | POSITIVE | Market expansion in XRAY's core vertical | | 2026-05-04 | Atlanta Dental Supply Agreement | POSITIVE | Distribution channel expansion | | 2026-04-13 | $13B Global Dental Labs Market | POSITIVE | Sector momentum |
Aggregate Sentiment: POSITIVE (83% positive headlines; only 1 neutral on profitability)
Sentiment Assessment & Technical Alignment
Critical Divergence Identified:
- News Sentiment: Overwhelmingly positive (5 of 6 headlines positive)
- Technical Momentum: Bearish (MACD crossover, negative OBV, declining volume)
- Price Action: Flat to negative (trading 17.3% below 200-day MA despite positive news)
Interpretation: Positive news is NOT translating into sustained buying. This suggests:
- Market has already priced in these expansion announcements
- Investors are concerned about margin pressure (noted in Q2 earnings) despite revenue growth
- Institutional sellers are using positive news as an opportunity to exit positions
- The disconnect between news and technicals raises questions about the durability of current positive narrative
Catalyst Identification
Immediate Catalysts (1-7 days):
- None identified in provided data
Near-term Catalysts (1-4 weeks):
- Earnings Date: November 5, 2026 — Critical test of guidance; given Q2 margin pressure warnings, expect market to focus on whether distribution expansion drives margin recovery
- Potential further distribution agreements (pattern of May and recent October announcements suggests ongoing negotiations)
Medium-term Catalysts (1-3 months):
- Q3 earnings implications from Midwest expansion ramp-up
- Competitive announcements from Envista or other major dental equipment players (mentioned as competitors in market forecasts)
Generated
News
All XRAY news →
Zacks Investment ResearchT3·1mo ago
GlobeNewswire Inc.T3·3mo ago
GlobeNewswire Inc.T3·3mo ago
GlobeNewswire Inc.T3·5mo ago
GlobeNewswire Inc.T3·6mo ago
GlobeNewswire Inc.T3·8mo ago
GlobeNewswire Inc.T3·8mo ago
GlobeNewswire Inc.T3·9mo ago
GlobeNewswire Inc.T3·9mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
23 of 25 under expected move
Avg Expected Move
8.75%
Avg Actual Move
4.13%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-01 | After-Close | 5.71% | 0.74% | 0.13x | Within |
| 2021-05-06 | After-Close | 4.51% | 1.60% | 0.35x | Within |
| 2021-08-05 | After-Close | 4.84% | 0.90% | 0.19x | Within |
| 2021-11-04 | After-Close | 6.77% | 1.58% | 0.23x | Within |
| 2022-02-28 | After-Close | 5.95% | 0.41% | 0.07x | Within |
| 2022-04-19 | After-Close | 10.55% | 1.64% | 0.16x | Within |
| 2022-08-04 | After-Close | 4.18% | 2.59% | 0.62x | Within |
| 2022-11-01 | After-Close | 10.00% | 9.10% | 0.91x | Within |
| 2023-01-11 | After-Close | 4.84% | 2.53% | 0.52x | Within |
| 2023-02-28 | After-Close | 6.96% | 1.86% | 0.27x | Within |
| 2023-05-03 | After-Close | 4.72% | 0.91% | 0.19x | Within |
| 2023-08-02 | After-Close | 7.33% | 3.42% | 0.47x | Within |
| 2023-11-02 | After-Close | 6.24% | 2.35% | 0.38x | Within |
| 2024-01-09 | After-Close | 9.03% | 2.35% | 0.26x | Within |
| 2024-02-29 | After-Close | 7.65% | 1.81% | 0.24x | Within |
| 2024-05-02 | After-Close | 6.62% | 0.32% | 0.05x | Within |
| 2024-07-31 | After-Close | 10.96% | 1.51% | 0.14x | Within |
| 2024-11-07 | Pre-Market | 10.84% | 28.02% | 2.58x | Exceeded |
| 2025-02-27 | Pre-Market | 14.89% | 8.83% | 0.59x | Within |
| 2025-05-08 | After-Close | 7.54% | 0.63% | 0.08x | Within |
| 2025-08-07 | Pre-Market | 14.62% | 3.29% | 0.23x | Within |
| 2025-11-06 | After-Close | 12.48% | 1.45% | 0.12x | Within |
| 2026-02-26 | After-Close | 14.16% | 15.50% | 1.09x | Exceeded |
| 2026-05-05 | After-Close | 16.27% | 2.02% | 0.12x | Within |
| 2026-08-06 | After-Close | 11.20% | 7.97% | 0.71x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
XRAY Options Activity & IV Rank
XRAY IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 54.1%
7-DTE IV: —
Expected Move: $1.12
7-DTE Move: $1.12
Days to Exp: 22 (2026-11-20)
Options Flow
Call Volume: 449
Put Volume: 102
P/C Volume: 0.227
BULLISH
Call OI: 1,453
Put OI: 1,488
P/C OI: 1.024
Total OI: 2,941
ATM Options Pricing
ATM Call: $0.42
ATM Put: $0.70
Call %: 4.4%
Put %: 7.3%
Chain Summary
Chain Volume: 1,412
Chain OI: 24,337
Last Updated: 10/29/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 75th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
75%
vs own history
GEX tilt
+0.35
OI-weighted, today
Vanna tilt
+0.39
δ-sensitivity to IV
Charm tilt
-0.23
δ-decay vs time
Vanna tilt +0.39: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
? What is this?
· 6 ATM contracts, 7k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 29 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 29 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)26.7MediumOct 29
Straddle Price (30 DTE)$1.12Oct 29
Beta Analysis
Risk Metrics
Beta: 1.1321
Alpha: -31.56%
Correlation: 0.3002
R-Squared: 9.0%
Stock Volatility: 47.9%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own XRAY
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $9.1M | #1637 of 3716 | +46.8% | 13F | |
| Citadel Hedge fund Ken Griffin | $8.1M | #1746 of 6285 | -45.3% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $3.9M | #527 of 997 | new | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $355K | #2721 of 3138 | -97.9% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $19K | #3742 of 4729 | -57.6% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
XRAY Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 199,825,000 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
10 filers$7.75M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $3.05M | 39.42% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $1.62M | 20.93% | 2026-06-30 |
| 3 | CONTINENTAL ADVISORS LLC | $824.87K | 10.65% | 2026-09-30 |
| 4 | IMC-Chicago, LLC Custodian | $700.26K | 9.04% | 2026-06-30 |
| 5 | Citadel Advisors LLC Custodian | $554.90K | 7.16% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $381.96K | 4.93% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $315.25K | 4.07% | 2025-09-30 |
| 8 | Simplex Trading, LLC Custodian | $125.20K | 1.62% | 2026-06-30 |
| 9 | Walleye Trading LLC | $90.19K | 1.16% | 2026-06-30 |
| 10 | Walleye Capital LLC | $79.58K | 1.03% | 2026-06-30 |
9 filers$6.34M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $2.05M | 32.31% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $1.47M | 23.20% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $922.01K | 14.53% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $680.10K | 10.72% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $323.61K | 5.10% | 2026-06-30 |
| 6 | Wolverine Trading, LLC Custodian | $276.16K | 4.35% | 2025-09-30 |
| 7 | Walleye Capital LLC | $251.46K | 3.96% | 2026-06-30 |
| 8 | Jane Street Group, LLC Custodian | $214.32K | 3.38% | 2026-06-30 |
| 9 | Walleye Trading LLC | $154.91K | 2.44% | 2026-06-30 |
XRAY Insider Trading (Form 4)
Latest: 2026-10-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Jonathan Jay Mazelsky | Director | Grant (A) | +3,323 RSU | — | EDGAR | |
| 2026-08-12 | John C. Fortson | EVP & CFO | Award (A) | +24,014 | — | EDGAR | |
| 2026-08-11 | Andrea L. Frohning | SVP, CHRO | Tax (F) | −802 | $12.12 | -$9.7K | EDGAR |
| 2026-07-01 | Jonathan Jay Mazelsky | Director | Grant (A) | +2,841 RSU | — | EDGAR | |
| 2026-06-18 | Jonathan Jay Mazelsky | Director | Buy (P) | +10,000 | $10.14 | $101.4K | EDGAR |
| 2026-06-16 | Clyde Hosein | Director | Buy (P) | +6,500 | $9.98 | $64.9K | EDGAR |
| 2026-06-15 | Michael J Barber | Director | Buy (P) | +15,175 | $9.88 | $150.0K | EDGAR |
| 2026-06-15 | Brian T Gladden | Director | Buy (P) | +9,985 | $10.02 | $100.0K | EDGAR |
| 2026-06-15 | Brian P McKeon | Director | Buy (P) | +10,000 | $10.12 | $101.2K | EDGAR |
| 2026-06-15 | Betsy D Holden | Director | Buy (P) | +10,086 | $9.88 | $99.7K | EDGAR |
| 2026-06-15 | Jonathan Jay Mazelsky | Director | Award (A) | +10,000 | $10.14 | $101.4K | EDGAR |
| 2026-06-05 | Michael J Barber | Director | Award (A) | +22,822 | — | EDGAR | |
| 2026-06-05 | James D Forbes | Director | Award (A) | +28,887 | — | EDGAR | |
| 2026-06-05 | Brian T Gladden | Director | Award (A) | +22,822 | — | EDGAR | |
| 2026-06-05 | Betsy D Holden | Director | Award (A) | +22,822 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
XRAY Insider Holdings
22 insiders · @ $9.61
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Simon D Campion | President, CEO | 239,837 | $2.30M | $497.3K | 23 | 2025-07-30 |
| 2 | Robert Anthony Johnson | SVP, Chief Supply Chain Office | 161,819 | $1.56M | $0 | 27 | 2026-03-06 |
| 3 | Daniel T Scavilla | President, CEO & Member of BOD | 157,754 | $1.52M | $0 | 10 | 2026-05-26 |
| 4 | Gregory T Lucier | Director | 101,665 | $977.0K | $2.61M | 47 | 2026-06-05 |
| 5 | Betsy D Holden | Director | 87,528 | $841.1K | $250.1K | 45 | 2026-06-15 |
| 6 | Richard C Rosenzweig | EVP, Corp Dev, GC & Secretary | 85,183 | $818.6K | $0 | 17 | 2025-10-15 |
| 7 | Leslie F Varon | Director | 80,364 | $772.3K | $100.0K | 45 | 2026-06-05 |
| 8 | Clyde Hosein | Director | 70,575 | $678.2K | $64.9K | 27 | 2026-06-16 |
| 9 | Janet S. Vergis | Director | 67,324 | $647.0K | $0 | 31 | 2026-06-05 |
| 10 | Andrea L. Frohning | SVP, CHRO | 63,190 | $607.3K | $0 | 20 | 2026-08-11 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
XRAY Board & Officers
As of SEC filings through Oct 2, 2026Directors 12
- Betsy D Holden · since Jan 14, 2018
- Leslie F Varon · since Jan 14, 2018
- Gregory T Lucier · on file since May 2019
- Janet S. Vergis · since Sep 25, 2019
- Clyde Hosein · since Sep 16, 2020
- Jonathan Jay Mazelsky · since May 24, 2023
- Brian T Gladden · since Jan 1, 2024
- Daniel T Scavilla · since Feb 5, 2025
- Michael J Barber · since Feb 6, 2025
- Donald Zurbay · since Jan 10, 2026
- Brian P McKeon · since Feb 27, 2026
- James D Forbes · since Feb 27, 2026
Officers 7
- Daniel T Scavilla · President, CEO & Member of BOD · listed since Aug 2025
- John C. Fortson · EVP & CFO · since Jul 20, 2026
- Robert Anthony Johnson · SVP, Chief Supply Chain Office · since Nov 28, 2022
- Kevin Czerney · VP, Chief Accounting Officer · since Nov 7, 2024
- Aldo Mariano Roberto Denti · EVP, Chief Commercial Officer · since Oct 6, 2025
- Lindi Rene Barton-Brobst · SVP, GC & Secretary · since Jun 8, 2026
- Andrea L. Frohning · SVP, CHRO · since Jul 17, 2023
Changes in the last 10 years (82)
| Jul 20, 2026 | John C. Fortson became EVP & CFO |
| Jun 8, 2026 | Lindi Rene Barton-Brobst became SVP, GC & Secretary |
| Feb 27, 2026 | James D Forbes became a director |
| Feb 27, 2026 | Brian P McKeon became a director |
| Feb 23, 2026 | The company announced the departure of Willie A Deese from the board in an SEC filing |
| Jan 10, 2026 | Donald Zurbay became a director |
| Oct 31, 2025 | The company announced the departure of Matthew E Garth as EVP & CFO in an SEC filing |
| Oct 15, 2025 | Richard C Rosenzweig reported in an SEC filing no longer being EVP, Corp Dev, GC & Secretary |
| Oct 6, 2025 | Aldo Mariano Roberto Denti became EVP, Chief Commercial Officer |
| Aug 12, 2025 | Daniel T Scavilla first listed as President, CEO & Member of BOD in an SEC filing |
| Jul 30, 2025 | Simon D Campion reported in an SEC filing no longer being a director |
| Jul 30, 2025 | Simon D Campion reported in an SEC filing no longer being President, CEO & Member of BOD |
| May 30, 2025 | Matthew E Garth became EVP & CFO |
| Feb 6, 2025 | Michael J Barber became a director |
| Feb 5, 2025 | The company announced the departure of Ilse Dorothea Wenzel from the board in an SEC filing |
| Feb 5, 2025 | Daniel T Scavilla became a director |
| Dec 2, 2024 | Herman Cueto became Interim CFO |
| Nov 7, 2024 | Kevin Czerney became VP, Chief Accounting Officer |
| Oct 15, 2024 | Richard C Rosenzweig listed as EVP, Corp Dev, GC & Secretary (previously SVP, Corp Dev, GC & Secretary) in SEC filings |
| Aug 15, 2024 | The company announced the departure of Glenn Coleman as Executive VP & CFO in an SEC filing |
| Mar 19, 2024 | Andreas G Frank listed as Exec VP/Chief Business Officer (previously Executive VP, Product Group) in SEC filings |
| Feb 27, 2024 | The company announced the departure of Eric Brandt from the board in an SEC filing |
| Jan 1, 2024 | Brian T Gladden became a director |
| Sep 27, 2023 | The company announced the departure of Harry M Jansen Kraemer Jr from the board in an SEC filing |
| Jul 17, 2023 | Andrea L. Frohning became SVP, CHRO |
| May 24, 2023 | Jonathan Jay Mazelsky became a director |
| Apr 10, 2023 | The company announced the departure of John P Groetelaars from the board in an SEC filing |
| Feb 27, 2023 | Richard C Rosenzweig became SVP, Corp Dev, GC & Secretary |
| Nov 28, 2022 | Robert Anthony Johnson became SVP, Chief Supply Chain Office |
| Nov 16, 2022 | John P Groetelaars first listed as Interim Chief Executive Office in an SEC filing |
| Sep 26, 2022 | Glenn Coleman became Executive VP & CFO |
| Sep 20, 2022 | The company announced the departure of Barbara W. Bodem as Interim CFO in an SEC filing |
| Sep 12, 2022 | Simon D Campion became a director |
| Sep 12, 2022 | Simon D Campion became President, CEO & Member of BOD |
| Sep 1, 2022 | The company announced the departure of Walter Petersohn as Chief Commercial Officer in an SEC filing |
| Aug 24, 2022 | Richard M Wagner listed as VP, Chief Accounting Officer (previously VP & Corporate Controller) in SEC filings |
| Aug 4, 2022 | The company announced the departure of Ranjit S Chadha as Chief Accounting Officer in an SEC filing |
| May 6, 2022 | Barbara W. Bodem became Interim CFO |
| May 2, 2022 | Willem T Appelo became SVP Chief Supply Chain Officer |
| Apr 25, 2022 | Andreas G Frank became Executive VP, Product Group |
| Apr 19, 2022 | The company announced the departure of Donald M Casey Jr. from the board in an SEC filing |
| Apr 19, 2022 | The company announced the departure of Donald M Casey Jr. from the board in an SEC filing |
| Apr 19, 2022 | The company announced the departure of Donald M Casey Jr. as President & CEO in an SEC filing |
| Apr 11, 2022 | The company announced the departure of Jorge M Gomez as EVP, CFO in an SEC filing |
| Apr 6, 2022 | John P Groetelaars became a director |
| Mar 18, 2022 | Donald M Casey Jr. first listed as a director in an SEC filing |
| Mar 8, 2022 | Erania Brackett no longer listed as a director in SEC filings |
| Feb 28, 2022 | Cheree H Johnson became SVP,Chief Legal Ofcr, GC &Sec |
| Feb 22, 2022 | Ilse Dorothea Wenzel became a director |
| Jan 19, 2022 | Erania Brackett first listed as a director in an SEC filing |
| Aug 11, 2021 | Erania Brackett listed as SVP, Chief Marketing Officer (previously Chief Marketing Officer) in SEC filings |
| Aug 2, 2021 | Erania Brackett became Chief Marketing Officer |
| Sep 16, 2020 | Clyde Hosein became a director |
| Aug 31, 2020 | Ranjit S Chadha became Chief Accounting Officer |
| Oct 28, 2019 | Lisa Yankie became Sr VP & Chief HR Officer |
| Sep 25, 2019 | Janet S. Vergis became a director |
| Aug 30, 2019 | Jorge M Gomez first on file as EVP, CFO |
| May 23, 2019 | Gregory T Lucier first on file as a director |
| May 22, 2019 | Matthew Coggin became SVP, Business Dev & Strategy |
| May 22, 2019 | Cord Friedrich Staehler became SVP, Chief Technology Officer |
| May 22, 2019 | Chidambaram Alagappa Chidambaram became SVP, Chief Digital Officer |
| Jan 21, 2019 | Daniel P Key became SVP,Chief Supply Chain Officer |
| Aug 13, 2018 | William E Newell listed as Chief Segment Officer (previously SVP Consumables Endo Ortho) in SEC filings |
| Aug 13, 2018 | Walter Petersohn listed as Chief Commercial Officer (previously Senior VP Americas RCO) in SEC filings |
| Jun 27, 2018 | Walter Petersohn listed as Senior VP Americas RCO (previously Chief Commercial Officer) in SEC filings |
| Mar 15, 2018 | William E Newell listed as SVP Consumables Endo Ortho (previously Sr Vice President, Consumables) in SEC filings |
| Mar 8, 2018 | William E Newell first on file as Sr Vice President, Consumables |
| Mar 8, 2018 | Markus Boehringer first on file as Sr Vice President, EMEA RCO |
| Mar 8, 2018 | Henning Mueller first on file as Group VP, Asia Pacific RCO |
| Mar 8, 2018 | Gregory Sheehan first on file as Group VP, Americas RCO |
| Mar 8, 2018 | Donald M Casey Jr. listed as President & CEO (previously Chief Executive Officer) in SEC filings |
| Mar 8, 2018 | Dominique Legros first on file as Sr VP Technologies & Equipment |
| Feb 12, 2018 | Donald M Casey Jr. became a director |
| Feb 12, 2018 | Donald M Casey Jr. became Chief Executive Officer |
| Jan 14, 2018 | Leslie F Varon became a director |
| Jan 14, 2018 | Betsy D Holden became a director |
| Nov 14, 2017 | Nicholas W Alexos listed as EVP, CFO (previously EVP, CAO) in SEC filings |
| Oct 10, 2017 | Nicholas W Alexos became EVP, CAO |
| Oct 10, 2017 | Keith J. Ebling became EVP, Secretary & Gen. Counsel |
| Oct 2, 2017 | Robert J. Size first listed as Interim President and COO in an SEC filing |
| Oct 2, 2017 | Mark Thierer first on file as Interim Chief Exec Officer |
| Jul 1, 2017 | Walter Petersohn became Chief Commercial Officer |
Not reported recently (35)
- Herman Cueto · Last reported as Interim CFO in an SEC filing dated Dec 4, 2024
- Andreas G Frank · Last reported as Exec VP/Chief Business Officer in an SEC filing dated Oct 15, 2024
- Richard M Wagner · Last reported as VP, Chief Accounting Officer in an SEC filing dated Jul 15, 2024
- Erania Brackett · Last reported as SVP, Chief Marketing Officer in an SEC filing dated Mar 19, 2024
- Cord Friedrich Staehler · Last reported as SVP, Chief Technology Officer in an SEC filing dated Apr 18, 2023
- Lisa Yankie · Last reported as Sr VP & Chief HR Officer in an SEC filing dated Apr 18, 2023
- John P Groetelaars · Last reported as Interim Chief Executive Office in an SEC filing dated Apr 18, 2023
- Cheree H Johnson · Last reported as SVP,Chief Legal Ofcr, GC &Sec in an SEC filing dated Jan 13, 2023
- Chidambaram Alagappa Chidambaram · Last reported as SVP, Chief Digital Officer in an SEC filing dated Jul 11, 2022
- Willem T Appelo · Last reported as SVP Chief Supply Chain Officer in an SEC filing dated May 12, 2022
- Arthur D Kowaloff · Last reported as a director in an SEC filing dated Apr 11, 2022
- Matthew Coggin · Last reported as SVP, Business Dev & Strategy in an SEC filing dated Apr 11, 2022
- Daniel P Key · Last reported as SVP,Chief Supply Chain Officer in an SEC filing dated Jan 19, 2022
- Keith J. Ebling · Last reported as EVP, Secretary & Gen. Counsel in an SEC filing dated Dec 2, 2021
- Michael C Alfano · Last reported as a director in an SEC filing dated May 26, 2021
- Francis J Lunger · Last reported as a director in an SEC filing dated Apr 12, 2021
- William E Newell · Last reported as Chief Segment Officer in an SEC filing dated Jun 5, 2020
- Maureen J. MacInnis · Last reported as Sr VP & Chief HR Officer in an SEC filing dated Oct 16, 2019
- Nicholas W Alexos · Last reported as EVP, CFO in an SEC filing dated Jul 16, 2019
- Markus Boehringer · Last reported as Sr Vice President, EMEA RCO in an SEC filing dated May 20, 2019
- Michael J Coleman · Last reported as a director in an SEC filing dated May 13, 2019
- Thomas Jetter · Last reported as a director in an SEC filing dated Apr 15, 2019
- David Beecken · Last reported as a director in an SEC filing dated Apr 15, 2019
- Henning Mueller · Last reported as Group VP, Asia Pacific RCO in an SEC filing dated Apr 15, 2019
- Dominique Legros · Last reported as Sr VP Technologies & Equipment in an SEC filing dated Jul 13, 2018
- Gregory Sheehan · Last reported as Group VP, Americas RCO in an SEC filing dated Apr 13, 2018
- Robert J. Size · Last reported as Interim President and COO in an SEC filing dated Feb 27, 2018
- Mark Thierer · Last reported as Interim Chief Exec Officer in an SEC filing dated Feb 27, 2018
- Bret W Wise · Last reported as a director in an SEC filing dated Feb 14, 2018
- Christopher T Clark · Last reported as President & CEO Technologies in an SEC filing dated Feb 14, 2018
- Ulrich Michel · Last reported as Executive Vice President & CFO in an SEC filing dated Oct 17, 2017
- Rainer Berthan · Last reported as Exec VP, Mfg & Supply Chain in an SEC filing dated Oct 17, 2017
- Jonathan I Friedman · Last reported as SVP,General Counsel, Secretary in an SEC filing dated Jul 18, 2017
- Jeffrey Slovin · Last reported as Chief Executive Officer in an SEC filing dated Jul 18, 2017
- James G Mosch · Last reported as President & CEO Consumables in an SEC filing dated Apr 25, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
XRAY Proposed Insider Sales (Form 144)
Latest: 2025-12-11
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2025-12-11 | LUCIER GREGORY T | DIRECTOR | 82,200 | $912.4K | 2025-12-08 | Tourmaline Partners, LLC | — | EDGAR |
| 2025-01-27 | Coleman Glenn | Former Officer | 15,759 | $311.2K | 2025-01-27 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2023-10-04 | Yankie Lisa | Former Officer | 3,587 | $118.7K | 2023-10-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2023-05-02 | BRANDT ERIC | Director | 6,200 | $261.5K | 2023-05-02 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-06-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-06-04 | 0000818479-26-000165 | EDGAR |
| 2026-05-05 | 0000818479-26-000147 | EDGAR |
| 2026-02-26 | 0000818479-26-000072 | EDGAR |
| 2026-02-24 | 0000818479-26-000058 | EDGAR |
| 2026-01-14 | 0000818479-26-000043 | EDGAR |
| 2026-01-13 | 0000818479-26-000024 | EDGAR |
| 2025-12-31 | 0000818479-25-000300 | EDGAR |
| 2025-11-25 | 0000818479-25-000281 | EDGAR |
| 2025-11-06 | 0000818479-25-000253 | EDGAR |
| 2025-11-06 | 0000818479-25-000254 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-05 | 0000818479-26-000149 | EDGAR |
| 2025-11-06 | 0000818479-25-000257 | EDGAR |
| 2025-08-07 | 0000818479-25-000155 | EDGAR |
| 2025-05-08 | 0000818479-25-000056 | EDGAR |
| 2024-11-07 | 0000818479-24-000093 | EDGAR |
| 2024-07-31 | 0000818479-24-000069 | EDGAR |
| 2024-05-02 | 0000818479-24-000036 | EDGAR |
| 2023-11-02 | 0000818479-23-000084 | EDGAR |
| 2023-08-07 | 0000818479-23-000064 | EDGAR |
| 2023-05-03 | 0000818479-23-000034 | EDGAR |
ETF Holders
103 ETFs hold XRAY
25 shown · $412.08M total exposure · 0.07% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJH iShares Core S&P Mid-Cap ETF | iShares (BlackRock) | 0.05% | $67.5M | $124.6B | 2026-10-28 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $56.9M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.06% | $48.9M | $77.1B | 2026-10-28 |
| 4 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.02% | $39.8M | — | 2026-09-30 |
| 5 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.04% | $25.9M | — | 2026-09-30 |
| 6 | VXF Vanguard Extended Market ETF | Vanguard | 0.02% | $20.0M | — | 2026-09-30 |
| 7 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.13% | $18.0M | $14.2B | 2026-10-28 |
| 8 | MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust | SPDR (State Street) | 0.05% | $14.1M | $25.9B | 2026-10-28 |
| 9 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.17% | $11.7M | $6.8B | 2026-10-28 |
| 10 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.03% | $11.2M | — | 2026-10-28 |
| 11 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.06% | $10.5M | — | 2026-09-30 |
| 12 | SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF | SPDR (State Street) | 0.05% | $10.1M | $18.6B | 2026-10-28 |
| 13 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.04% | $10.1M | — | 2026-05-31 |
| 14 | IJJ iShares S&P Mid-Cap 400 Value ETF | iShares (BlackRock) | 0.11% | $9.5M | $8.7B | 2026-10-28 |
| 15 | KOMP State Street® SPDR® S&P Kensho New Economies Composite ETF | SPDR (State Street) | 0.30% | $7.7M | $2.6B | 2026-10-28 |
| 16 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $6.9M | — | 2026-10-28 |
| 17 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.07% | $5.6M | — | 2026-10-28 |
| 18 | VHT Vanguard Health Care ETF | Vanguard | 0.02% | $5.4M | — | 2026-09-30 |
| 19 | VRP Invesco Variable Rate Preferred ETF | Invesco | 0.18% | $5.4M | — | 2026-10-28 |
| 20 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.13% | $5.3M | $4.3B | 2026-10-28 |
| 21 | BSCU Invesco BulletShares 2030 Corporate Bond ETF | Invesco | 0.19% | $5.2M | — | 2026-10-28 |
| 22 | FNDX Schwab Fundamental U.S. Large Company ETF | Nport | 0.02% | $4.9M | — | 2026-05-31 |
| 23 | BSMC Brandes U.S. Small-Mid Cap Value ETF | Nport | 2.37% | $3.9M | — | 2026-06-30 |
| 24 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.12% | $3.8M | $3.2B | 2026-10-28 |
| 25 | DFAT Dimensional US Targeted Value ETF | Dimensional | 0.01% | $3.7M | — | 2026-10-28 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-2.74
TTM Revenue
$3.64B
TTM Net Income
$-546.00M
TTM Op. Cash Flow
$319.00M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $898.00M | $37.00M | $0.18 | $99.00M |
| Q1 '26 | 2026-03-31 | $880.00M | $-10.00M | $-0.05 | $40.00M |
| Q4 '25 | 2025-12-31 | $961.00M | $-146.00M | $-0.73 | $101.00M |
| Q3 '25 | 2025-09-30 | $904.00M | $-427.00M | $-2.14 | $79.00M |
| Q2 '25 | 2025-06-30 | $936.00M | $-45.00M | $-0.22 | $48.00M |
| Q1 '25 | 2025-03-31 | $879.00M | $20.00M | $0.10 | $7.00M |
| Q4 '24 | 2024-12-31 | $905.00M | $-430.00M | $-2.13 | $87.00M |
| Q3 '24 | 2024-09-30 | $951.00M | $-494.00M | $-2.46 | $141.00M |
| Q2 '24 | 2024-06-30 | $984.00M | $-4.00M | $-0.02 | $208.00M |
| Q1 '24 | 2024-03-31 | $953.00M | $18.00M | $0.09 | $25.00M |
| Q4 '23 | 2023-12-31 | $1.01B | $67.00M | $0.32 | $160.00M |
| Q3 '23 | 2023-09-30 | $947.00M | $-266.00M | $-1.25 | $134.00M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.42
P/S
0.53
EV/EBITDA
6.89
EV/Sales
1.01
ROE
-40.4%
ROA
-10.5%
Div Yield
5.10%
FCF Yield
16.61%
Debt/Equity
1.48
Current Ratio
—
Market Cap
$1.92B
as of 2026-10-29
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
25.53M
SI % of Float
12.88%
Days to Cover
4.46
Short Vol Ratio
58.7%
Free Float
198.20M
Float %
99.4%
Short interest 2026-09-30 • Short volume 2026-10-29 • Float 2026-08-14